MEDIA CENTER - 2015 - 2016

October 25, 2016
APIM Therapeutics will be participating at BioEurope Partnering meeting, in Cologne, Germany (November 7-9, 2016).

August 25, 2016
APIM Therapeutics will be participating at the Nordic Life Sciences Days conference in Stockholm (September 14-15, 2016). A presentation during the Biotechnology Track: R&D Services/Therapeutics & Diagnostics/Others will be given on Sept. 14, 17.15.

June 1, 2016
APIM Therapeutics appoints Professor Justin Stebbing at its Advisory Board. Dr. Stebbing, a Professor of Cancer Medicine and Oncology, and a Consultant Oncologist at Imperial College and Imperial College Healthcare NHS Trust, is a world-renowned expert in clinical oncology with over 500 publications to his record. His expertise spans clinical practice as well as early and late stage trials of new drugs, mechanisms of disease and prognostic indicators.

May 19, 2016
APIM Therapeutics's CSO and NTNU Professor Marit Otterlei presents efficacy results obtained with ATX-101 in bladder and basal-like breast cancer models at the AACR Precision Medicine Series Conference: Targeting the Vulnerabilities of Cancer (Miami, May 16-19, 2016). A copy of the poster presented is available here.

May 13, 2016
APIM Therapeutics will be participating at the BIO 2016 International Convention in San Francisco (June 6-9, 2016).

April 11, 2016
APIM Therapeutics will be participating at the BioTrinity 2016 and BioEquity 2016 partnering meetings held on April 25-27 and May 10-11, 2016 in London and Copenhagen, respectively.

March 23, 2016
APIM Therapeutics's CSO and NTNU Professor Marit Otterlei presents latest results obtained with ATX-101 in preclinical efficacy models in the 14th International Congress on Targeted Anticancer Therapies, 21-23 March, 2016, n Washington, USA. A copy of the poster presented is available here.

February 19, 2016
APIM Therapeutics will be participating at the 9th Annual European Life Science CEO Forum & Exhibition held on 15th-16th March 2016 in Zurich.

February 3, 2016
APIM Therapeutics will be participating at the 10th Swiss-Scandinavian Bio-Business Seminar held on February 10, 2016 at the SIX Stock Exchange building in Zurich.

January 15, 2016
APIM Therapeutics announced today that it has completed a new financing round by existing investors. This financing will enable the company to prepare for entry into first-in-man clinical studies within 2016.

June 17, 2015
APIM Therapeutics appoints Martin Welschof Ph.D to its Board of Directors. Martin, currently serving as the CEO of Opsona Therapeutics, adds significant development and commercialization expertise to the Board of APIM Therapeutics. For more information on Dr. Welschof's experience, please visit About Us.

May 7, 2015
APIM Therapeutics's CEO, Kostas Alevizopoulos, will be presenting the company's latest development plans in the BioTrinity Investor Conference in London (May 11-13, 2015). 

May 6, 2015
UroToday.com Beyond the Abstract program publishes commentary by APIM Therapeutics's CSO Prof. Otterlei discussing the properties of PCNA targeting peptides such as ATX-101 to increase the anticancer efficacy of intravesical mitomycin-C therapy in bladder cancer. A copy of the commentary is available here.

March 30, 2015
APIM Therapeutics announced today that it has completed a new financing round by existing and new investors. This financing will enable the company to finalize preclinical development of ATX-101 aiming to file two clinical trial applications in late 2015 - early 2016.

March 20, 2015
Cell Signaling publishes an important scientific paper authored by APIM Therapeutics's CSO and NTNU Professor Marit Otterlei and co-workers. The paper describes a new platform/scaffold role of PCNA in the cytosol affecting key cellular signaling pathways such as the AKT, PI-3K and MAPK pathways. A pdf copy of the published article is available here.

Visit Media Center 2017
Visit Media Center 2013 & 2014
Visit Media Center 2012
Visit Media Center 2010 & 2011

To learn more the APIM-motif, ATX-101 and PCNA, please see attached the publications (given as pdf files):

1. Gilljam KM et al, 2009. Identification of a novel, widespread, and functionally important PCNA-binding motif. J Cell Biol 186, pp645-654.

2. Müller R et al, 2013. Targeting proliferating cell nuclear antigen and its protein interactions induces apoptosis in multiple myeloma cells. PLoS One. 2013 Jul 31;8(7).

3. Baglo Y et al, 2014. Enhanced efficacy of bleomycin in bladder cancer cells by photochemical internalization. Biomed Res Int. 2014;2014:921296.

4. Gederaas OA et al, 2014. Increased Anticancer Efficacy of Intravesical Mitomycin C Therapy when Combined with a PCNA Targeting Peptide. Transl Oncol. 2014 Dec;7(6):812-23.

5. Olaisen C et al, 2014. PCNA-interacting peptides reduce Akt phosphorylation and TLR-mediated cytokine secretion suggesting a role of PCNA in cellular signaling. Cell Signal. 2015 Jul;27(7):1478-87.

The following posters presented in TAT and AACR 2016 meetings provide latest efficacy data in bladder and breast cancer models as well as genomic and kinomic analysis conducted in these tumors:

6. Poster presented in the 14th International Congress on Targeted Anticancer Therapies.

7. Poster presented in the AACR Precision Medicine Series Conference: Targeting the Vulnerabilities of Cancer. 

For an excellent review discussing the druggability of PCNA and ATX-101:

8. Wang Shao-Chun, 2014. PCNA: a silent housekeeper or a potential therapeutic target? Trends Pharmacol Sci. 2014 Apr;35(4):178-186.

 

Trondheim

APIM Therapeutics AS is a spin-off from the Norwegian University of Science and Technology (NTNU).

Visit our About Us page to find out more.

About NTNU
The Norwegian University of Science and Technology (NTNU) is one of the most prominent Academic centers in Norway. It is home to a growing number of spin-out companies including APIM Therapeutics AS. To learn more about NTNU, please see www.ntnu.no.

About Sarsia Seed
Sarsia Seed is a Norwegian seed stage life science fund that has invested in APIM Therapeutics. Visit www.sarsiaseed.com to find out more.

About Birk Venture
Birk Venture is a Scandinavian venture company exclusively focusing on innovative life science companies. Visit www.birkventure.no to find out more.

About Norsk Innovasjonskapital
Norsk Innovasjonskapital is a leading Norwegian venture capital company focusing on selective investments in various industry fields including life sciences. Visit www.televenture.no to find out more.